Filgotinib Progress At Higher Dose Justifies Gilead's Gamble
News that Belgium's Galapagos and partner Gilead are to advance a higher dose of JAK1 inhibitor filgotinib into Phase III help allay lingering doubts over testicular toxicity with the drug, the rights to which AbbVie had unexpectedly handed back.
You may also be interested in...
Gilead's Strong HIV Quarter Plus Bictegravir May Portend Sector Dominance
Sales of Gilead's TAF-based regimens for HIV continue to grow and should be augmented by elvitegravir successor bictegravir. The company's future growth is unclear, however, without M&A.
AbbVie May Be Poised For An Oral RA Smack Down
Upadacitinib hit the primary endpoints in the first of six Phase III studies in rheumatoid arthritis, as well as several important secondary endpoints. Continued success in Phase III will position the candidate well in the race to market with Lilly.
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Gilead CEO John Milligan, pressured by an analyst, gave a brief rundown of the company's strategic priorities as investors wait for the company to spend its $34bn in cash on revenue-increasing opportunities to offset declining hepatitis C drug sales.